A brief history of the development of diabetes medications

Diabetes Spectrum

Volumn 27, Issue 2, 2014, Pages 82-86

  White Jr , John R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BROMOCRIPTINE; BUFORMIN; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN INSULIN; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LIXISENATIDE; MEGLITINIDE; METFORMIN; PHENFORMIN; PIOGLITAZONE; PRAMLINTIDE; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOLAZAMIDE; TROGLITAZONE; UNINDEXED DRUG;

ANTIDIABETIC ACTIVITY; BLADDER CANCER; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG SAFETY; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART INFARCTION; HISTORY OF MEDICINE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIVER FAILURE; MAURIAC SYNDROME; PANCREAS ISLET BETA CELL; SHORT SURVEY;

EID: 84901950744     PISSN: 10409165     EISSN: 19447353     Source Type: Journal    
DOI: 10.2337/diaspect.27.2.82     Document Type: Short Survey

References (26)

1. Sanders LJ: From Thebes to Toronto and the 21st century: an incredible journey. Diabetes Spectrum 15:56-60, 2002
2. Bliss M: The Discovery of Insulin. Chicago, University of Chicago Press, 1982
3. Galloway JA: Diabetes Mellitus. 9th ed. Indianapolis, Ind., Eli Lilly and Company, 1988
4. Daneman D, Drash AL, Lobes LA, Becker DJ, Baker LM, Travis LB: Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome). Diabetes Care 4:360-365, 1981 (Pubitemid 12201585)
5. Defeat Diabetes, Foundation: History of diabetes in timeline. Available from http://www.defeatdiabetes.org/about-diabetes/text.asp?id=Diabetes-Timeline. Accessed 4 December 2013
6. Medscape: FDA rejects Novo Nordisk's insulin degludec [article online]. 11 February 2013. Available from http://www.medscape.com/viewarticle/779077. Accessed 2 January 2014
7. White JR: Overview of the medications used to treat type 2 diabetes. In Medications for the Treatment of Diabetes. White JR, Campbell RK, Eds. Alexandria. Va., American Diabetes Association, 2008, p. 5-15
8. Frank E, Nothnamm M, Wagner A: Über synthetische dargestellte Korper mit Insulinartiger Wirkung auf den normallen und diabetisched Organismus. Klin Wchnschr 5:2011, 1926
9. Alberti KGMM, Zimmet P, Defronzo RA: International Textbook of Diabetes Mellitus. 2nd ed. New York, John Wiley & Sons, 1997
10. Levine R: Sulfonylureas: background and development of the field. Diabetes Care 7 (Suppl. 1):3-7, 1984
11. Quianzon CCL, Cheikh I: History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspect. Published online 15 October 2012. (doi: 10.3402/jchimp.v2i3.19081)
12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Farrannini E, Nauck M, Peters A, Tsapas A, Wender R, Mathhews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364-1379, 2012
13. Kendall DM: Thiazolidinediones: the case for early use. Diabetes Care 29:154-157, 2006
14. Lumpkin MM: Troglitazone: presentation to advisory committee. Published 19 May 2000. Available from www.fda.gov/ohrms/dockets/ac/00/slides/3615s1a.PPT. Accessed 4\ December 2013
15. Nature World News: FDA eases restrictions on Glaxo diabetes drug Avandia. Published 26 November 2013. Available from http://www.natureworldnews.com/ articles/5075/20131126/fda-eases-restrictions-glaxos-drug.htm. Accessed 4 December 2013
16. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-37) in diabetic and non-diabetic patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
17. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1 (7-37) in diabetic and non-diabetic patients with diabetes mellitus. Diabetes Care 15:270-276, 1992
18. Aroda VR, Ratner R: The safety and tolerability of GLP-1 receptor agonist in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 27:528-542, 2011
19. diatribe: Eli Lilly submits GLP-1 dulaglutide to FDA and unveils injection device [article online]. Available from http://diatribe.us/issues/59/ new-now-next/5. Accessed 4 December 2013
20. Stuart C: Sanofi pull lixisenatide's FDA application [article online]. Cardiovascular Business. Available from http://www.cardiovascularbusiness.com/ topics/prevention/sanofi-pulls-lixisenatide%E2%80%99s-fda-application. Accessed 4 December 2013
21. Neumiller JJ: Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonist and DPP-4 inhibitors. J Am Pharm Assoc 49 (Suppl. 1):S14-S29, 2009
22. White J: Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT-2 inhibition. Clinical Diabetes 28:5-10, 2010
23. Monami M, Nardini C, Mannucci E: Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. Electronically published ahead of print on 29 December 2013 (doi: 0.1111/dom.12244)
24. Forbes.com: FDA approves first SGLT2 inhibitor for diabetes [article online]. 29 March 2013. Available from http://www.forbes.com/sites/larryhusten/ 2013/03/29/fda-approves-first-sglt2-inhibitor-for-diabetes. Accessed 3 January 2014
25. Nainggolan L: Life expectancy greatly improved in type 1 diabetes [article online]. 25 September 2013. Available from http://www.medscape.com/ viewarticle/811610. Accessed 4 December 2013
26. Goodkin G: Mortality factors in diabetes: a 20 year mortality study [Abstract]. J Occup Med 17:716-721, 1975